Pamela L. Kunz, MD

Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses tumor response in the CLARINET study, which examined lanreotide depot versus placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Pamela L. Kunz, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses some anticipated trial results for patients with neuroendocrine and carcinoid tumors.

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the effort to identify molecular subtypes of gastric cancer.

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses current and future treatment options for patients with neuroendocrine tumors (NETs).